CN Mobile Logo

Search form


LHRH Agonist Matches Ovariectomy Results: SWOG

LHRH Agonist Matches Ovariectomy Results: SWOG

PARIS--The luteinizing hormone-releasing hormone (LHRH) agonist goserelin (Zoladex) proved as effective as surgical ovariectomy in premenopausal women with estrogen and/or progestogen receptor-positive metastatic breast cancer, a randomized multicenter study has shown.

Investigator Charles W. Taylor of the University of Arizona, Tucson, presented the results of the study, SWOG 8692, at the Sixth International Congress on Anti-Cancer Treatment. The trial was conducted by investigators from the Southwestern Oncology Group, North Central Cancer Treatment Group, and Eastern Cooperative Oncology Group.

The 135 participants in this study were assigned to undergo either surgical ovariectomy or treatment with monthly subcutaneous injections of goserelin, 3.6 mg. None had undergone previous chemotherapy or hormonal therapy, except in the adjuvant setting, and none had brain metastases or life-threatening lung or liver metastases.

Dr. Taylor reported that both failure-free and overall survival were equivalent with the two modes of ovarian ablation. The time to treatment failure averaged 3 months in surgically treated patients and 6 months in the goserelin group; median overall survival rates were 33 months and 35 months, respectively. Rates of objective tumor regression were similarly low in both treatment groups.

By clicking Accept, you agree to become a member of the UBM Medica Community.